MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

Electroporation Systems

ATx_03_shadow-132@2x

ATx

From small to medium static Electroporation.

STx_04_shadow@2x

STx

Transfect up to 20 billion cells with scalable static or flow-through electroporation.

GTx_05_shadows@2x

GTx

Transfect up to 20 billion cells with our clinically validated and cGMP compliant flow-through electroporation.

VLX-right-132@2x

VLx

For gram scale protein production.